Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. brain health
Show results for
Products
Services
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Brain Health Articles & Analysis

56 news found

Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...

ByAlfa Chemistry


Synaptive Medical to Test New Software for Brain Surgery Planning at Unity Health Toronto

Synaptive Medical to Test New Software for Brain Surgery Planning at Unity Health Toronto

Planning brain surgery is a delicate process that requires precision to avoid damaging surrounding brain tissue and to prevent post-surgery complications. ...

BySynaptive Medical


Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes to regulating brain function. ...

BySage Therapeutics


Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

(Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ...

BySage Therapeutics


Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. ...

BySage Therapeutics


Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

(Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 10:55 a.m. ...

BySage Therapeutics


Altoida to Present at Upcoming Industry Conferences

Altoida to Present at Upcoming Industry Conferences

Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...

ByAltoida, Inc.


Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measure for a Randomized, PlaceboControlled, Double-Blind Study of XPro™ in Patients ...

ByOxford Brain Diagnostics Ltd.


Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes to regulating brain function. ...

BySage Therapeutics


Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

(Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ...

BySage Therapeutics


Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing ...

ByAltoida, Inc.


Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease

The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing ...

ByAltoida, Inc.


Mission Based Media Launches Alzheimer`s Podcast, the Newest Podcast Miniseries on Health Unmuted

Mission Based Media Launches Alzheimer`s Podcast, the Newest Podcast Miniseries on Health Unmuted

The launch coincides with the observation of Alzheimer's and Brain Awareness Month, and follows the successful pilot of the first Health Unmuted miniseries, COPD Podcast. ...

ByAltoida, Inc.


Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer

Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer

Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. ...

ByAltoida, Inc.


Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform

Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform

Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. ...

ByAltoida, Inc.


VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders

VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders

The partnership will pioneer the integration of Total Brain’s proprietary mental health and brain performance database with VeriSIM Life’s BIOiSIM AI-enabled drug development decision engine to enable new psychiatric and neurological therapies. The Total Brain platform helps more than one million individuals improve ...

ByVeriSIM Life


Altoida Announces Partnership with Click Therapeutics to Power Clinical Trials with Digital Cognitive Assessment

Altoida Announces Partnership with Click Therapeutics to Power Clinical Trials with Digital Cognitive Assessment

Its products work by combining clinical and engagement sciences to stimulate and modulate targeted brain processes, delivering novel, holistic digital interventions to disrupt specific thought patterns, emotions and behaviors and establish new neural connections and activity for durable and lasting results. ...

ByAltoida, Inc.


Eg Technology And Health Enterprise East Announce Winners Of The 2021 Innovation Voucher Award

Eg Technology And Health Enterprise East Announce Winners Of The 2021 Innovation Voucher Award

Following the success of the 2020 Innovation Voucher Award, won by Mr Ryan Mathew and Dr Heiko Wurdak for their Mini-brain benchtop test, eg technology and Health Enterprise East (HEE) are pleased to announce, not one, but two joint winners of this year’s Innovation Voucher Award. ...

Byeg Technology Ltd


Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment

Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment

The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain timely and accurate health insights using GN Group’s device technologies and, ultimately, to enable early detection of neurodegenerative diseases such as MCI and Alzheimer’s Disease. ...

ByAltoida, Inc.


Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up to US$2.1M investment from the Alzheimer’s Drug Discovery Foundation (ADDF). ...

ByOptina Diagnostics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT